Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC

NCT06739928 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer Extensive Stage

Interventions

DRUG: Irinotecan liposome (II) combined with adebrelimab and carboplatin
DRUG: etoposide combined with adebrelimab and carboplatin

Sponsor

Guangzhou Institute of Respiratory Disease